EICHORCondition: NASH - Nonalcoholic Steatohepatitis · Sponsor: Madrigal Pharmaceuticals, Inc.
A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| East Valley Family Physicians | Chandler, Arizona, United States | — |
| The Institute for Liver Health - Chandler | Chandler, Arizona, United States | — |
| The Institute for Liver Health - Glendale | Glendale, Arizona, United States | — |
| Desert Clinical Research | Mesa, Arizona, United States | — |
| Adobe Gastroenterology | Tucson, Arizona, United States | — |
| The Institute for Liver Health - Tucson | Tucson, Arizona, United States | — |
| Arkansas Gastroenterology | North Little Rock, Arkansas, United States | — |
| Fresno Clinical Research Center | Fresno, California, United States | — |
| National Research Institute - Huntington Park | Huntington Park, California, United States | — |
| University of California San Diego | La Jolla, California, United States | — |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | — |
+ 235 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03900429